According to VentiRx Pharmaceuticals, a Phase I clinical trial of its VTX-1463 nasal spray for the treatment of allergic rhinitis demonstrated that once-weekly administration of the drug produced a significantly greater reduction in total nasal symptom scores than did a placebo. VTX-1463 is a selective toll-like receptor 8 (TLR8) agonist. Read the company’s press release.
Positive results for VTX-1463 nasal spray
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
